Simulated cost-effectiveness of a novel precision-guided dosing strategy in adult patients with Crohn's disease initiating infliximab maintenance therapy.
Elmar R AlizadehThierry DervieuxSeverine VermeireMarla DubinskyGeert D'HaensDavid LaharieAndrew ShimByron P VaughnPublished in: Pharmacotherapy (2024)
PGD provides clinical and QoL benefits by maintaining remission and avoiding IFX failure; it is the most cost-effective under conservative assumptions.